Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Long-Term Debt
Nurexone Biologic Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Long-Term Debt
$20k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
Long-Term Debt
CA$632m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Long-Term Debt
CA$805.4m
|
CAGR 3-Years
47%
|
CAGR 5-Years
46%
|
CAGR 10-Years
32%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Long-Term Debt
CA$459.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Long-Term Debt
CA$988m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
14%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Long-Term Debt
$127.1k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Long-Term Debt?
Long-Term Debt
20k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Long-Term Debt amounts to 20k USD.
What is Nurexone Biologic Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 1Y
0%
Over the last year, the Long-Term Debt growth was 0%.
